On July 30, 2024 Shenzhen Synthetica Pioneering Co., Ltd. (Synthetica), a biotech startup specializing in synthetic biology for engineering novel living bacterial therapeutics, reported that it has recently closed a Series A funding round, led by Boehringer Ingelheim Venture Fund and Temasek, with additional participation from Lenovo Capital, Fosun Health Capital and ATLATL Summer Fund (Press release, Shenzhen Synthetica Pioneering, JUL 30, 2024, View Source [SID1234645183]). The funding will be used to fast-track Synthetica’s oncolytic bacterial pipelines into clinical trials.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Headquartered in Shenzhen, China, Synthetica is a biotech company founded in 2023, specializing in genetic circuit engineering and precise control of genes and payloads to treat various diseases. Synthetica is currently focused on developing oncolytic bacterial therapies for treating solid tumors. With a deep understanding of biological mechanisms and advanced synthetic biology techniques, Synthetica is aiming to create innovative bacterial treatments that are safe, effective, versatile, and minimally invasive to fight cancer.
Synthetica’s CEO, Yingke He stated: "Securing this funding marks a pivotal moment for our young company as we advance the frontier of cancer treatment. Our innovative synthetic biology approach to developing oncolytic bacteria offers new hope for more effective and targeted therapies. We extend our heartfelt thanks to our technology contributors and financial investors for their trust and support. Together we will drive this breakthrough science forward, and make significant advancements in the fight against cancer, bringing us closer to transforming patients’ lives worldwide."
Dr. Mia Hu, Investment Director, Boehringer Ingelheim Venture Fund, commented: "Boehringer Ingelheim Venture Fund (BIVF) is committed to invest in innovative therapeutics that address unmet patient needs. Oncolytic bacterial therapy remains a key strategic focus for the Boehringer Ingelheim Venture Fund. The Synthetica team, with its years of expertise in quantitative synthetic biology, is pioneering the development of innovative bacterial therapies for various indications. We are thrilled to support Synthetica in their ongoing efforts to advance next-generation bacterial therapies for the treatment of solid tumors, with the ultimate goal of transforming the lives of more people living with cancer."